Encapsulated formulation of curcumin together with RTKI and doxorubicin (IMX-110) is currently in a phase 1/2 trial as it has an advantage of targeting cancer cells with doxorubicin while inhibiting activation of signal transducer and activator of transcription 3 (STAT3) and NF-kB, as well as PI3K/AKT/mTOR [182,183] by curcumin, thus inhibiting the evolution of resistance [184,185]. This evidence concerns the gene NFKB1 and cancer.